Enhanced Versus Standard Blood Pressure Lowering on Intracranial Aneurysm Rupture or Growth China Antihypertensive Trial for Intracranial Aneurysm (ChATIA-1)

Launched by BEIJING TIANTAN HOSPITAL · Jul 4, 2023

Keywords

ClinConnect Summary

The ChATIA-1 trial is studying how different levels of blood pressure control can affect patients with unruptured intracranial aneurysms (UIA), which are bulges in blood vessels in the brain that have not yet burst. The trial aims to find out if lowering blood pressure more aggressively (enhanced blood pressure lowering) is safe and beneficial for these patients compared to standard blood pressure control. This research is important because it will help doctors make better decisions about managing blood pressure in patients with UIA, ultimately leading to improved care.

To be eligible for this trial, participants need to be aged between 18 and 75, have a single unruptured aneurysm that is less than 7 mm in size, and have a history of high blood pressure that is currently being treated. Patients must also be of Chinese ethnicity and have good adherence to their medication. If you join the trial, you'll be randomly assigned to one of two groups: one that receives standard blood pressure treatment and another that receives enhanced treatment. Throughout the trial, you'll be monitored closely to ensure your safety and the effectiveness of the treatment. This study is currently recruiting participants, so if you think you might be eligible, it could be a valuable opportunity to contribute to medical research.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 18-75;
• • 2. Chinese ethnicity;
• • 3. History of hypertension (as diagnosed per standard of care)
• • 4. Under active treatment for hypertension: In the past one month (before enrollment), the blood pressure was controlled at the borderline statue (systolic pressure as 120-140 mmHg, diastolic pressure as 70-80 mmHg) ;
• • 5. Good medication adherence (Morisky Medication Adherence Scale ≥6)
• • 6. Single unruptured intracranial aneurysm (UIA) identified by computational tomography angiography, magnetic resonance angiography or digital subtraction angiography within 1 year, and receiving conservative treatment
• • 7. Maximal size of UIA at largest dimension \< 7mm;
• • 8. UIA is regular (no bleb(s) or secondary aneurysm(s) protruding from the UIA fundus or bi-/multi-lobular UIA fundus). The regular shape and aneurysm size will be evaluated by the central core lab (including a senior neuroradiologist and two neurosurgeons) based on the three-dimensional angiographic imaging;
• Exclusion Criteria:
• • 1. Neurological symptom related to UIA, such as sentinel headache, oculomotor paralysis and so on;
• • 2. Additional active intracranial disease including vasculopathy, arteriovenous malformation/fistula, cancer, traumatic brain injury etc;
• • 3. Fusiform, dissecting, blister, traumatic, mycotic/bacterial, myxomatous, and tumor-associated UIAs are excluded;
• • 4. History of polycystic kidney disease, rheumatic disease or autoimmune disease;
• • 5. Family history of intracranial aneurysm (defined when two direct relatives of patients within three generations have intracranial aneurysms or aneurysmal subarachnoid hemorrhage);